Qianqian Liu

Qianqian Liu

Auto-generated profile, based on publicly available information

Qianqian Liu

Department of Respiratory and Critical Care Medicine, Chengdu Integrated TCM and Western Medical Hospital, Chengdu City, Sichuan Province, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
XLXixi Liu
Xixi Liu
CCChunyuan Chen
Chunyuan Chen
YJYaling Jiang
Yaling Jiang
MWMeidan Wan
Meidan Wan
BJBin Jiao
Bin Jiao
LSLu Shen
Lu Shen
Inadequate osteogenesis and excessive adipogenesis of bone marrow mesenchymal stem cells (BMSCs) are key factors in the pathogenesis of osteoporosis. Patients with Alzheimer's disease (AD) have a higher incidence of osteoporosis than healthy adults, but the underlying mechanism is not clear. Here, we show that brain-derived extracellular vesicles (EVs) from adult AD or wild-type mice can cross the blood-brain barrier to reach the distal bone tissue, while only AD brain-derived EVs (AD-B-EVs) significantly promote the shift of the BMSC differentiation fate from osteogenesis to adipogenesis and induce a bone-fat imbalance. MiR-483-5p is highly enriched in AD-B-EVs, brain tissues from AD mice, and plasma-derived EVs from AD patients. This miRNA mediates the anti-osteogenic, pro-adipogenic, and pro-osteoporotic effects of AD-B-EVs by inhibiting Igf2. This study identifies the role of B-EVs as a promoter of osteoporosis in AD by transferring miR-483-5p.

1 September 2021 in Microbial Pathogenesis
Verified
Journal Article
Closed access
QLQianqian Liu
Qianqian Liu
WLWenzhang Li
Wenzhang Li
YCYunfeng Chen
Yunfeng Chen

19 March 2021 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
BTBO TANG
BO TANG
LSLongxiang Su
Longxiang Su
DLDongkai Li
Dongkai Li
YWYe Wang
Ye Wang
QLQianqian Liu
Qianqian Liu
XZXiang Zhou
Xiang Zhou
To investigate the optimal target e of lactate kinetics at different time during the resuscitation, the factors that influence whether the kinetics achieve the goals, and the clinical implications of different clinical phenotypes. Patients with hyperlactatemia between May 1, 2013 and December 31, 2018 were retrospectively analyzed. Demographic data, basic organ function, hemodynamic parameters at ICU admission (T0) and at 6 h, 12 h, 24 h, 48 h, and 72 h, arterial blood lactate and blood glucose levels, cumulative clinical treatment conditions at different time points and final patient outcomes were collected. A total of 3298 patients were enrolled, and the mortality rate was 12.2%. The cutoff values of lactate kinetics for prognosis at 6 h, 12 h, 24 h, 48 h, and 72 h were 21%, 40%, 57%, 66%, and 72%. The APACHE II score, SOFA score, heart rate (HR), and blood glucose were risk factors that correlated with whether the lactate kinetics attained the target goal. Based on the pattens of the lactate kinetics, eight clinical phenotypes were proposed. The odds ratios of death for clinical phenotypes VIII, IV, and II were 4.39, 4.2, and 5.27-fold of those of clinical phenotype I, respectively. Stepwise recovery of lactate kinetics is an important resuscitation target for patients with hyperlactatemia. The APACHE II score, SOFA score, HR, and blood glucose were independent risk factors that influenced achievement of lactate kinetic targets. The cinical phenotypes of stepwise lactate kinetics are closely related to the prognosis.

24 November 2025 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
QLQianqian Liu
Qianqian Liu
WQWenqi Qing
Wenqi Qing
SGShanshan Guo
Shanshan Guo
YWYongsheng Wang
Yongsheng Wang
YCYunfeng Chen
Yunfeng Chen
JLJie Liu
Jie Liu
Hermansky–Pudlak syndrome (HPS) is a rare autosomal recessive disorder caused by defects in lysosome-related organelles (LROs). Eleven HPS subtypes have been identified, each associated with mutations in distinct genes, with HPS-4 being among the rarer forms. Here, we present a 38-year-old Chinese woman with oculocutaneous albinism (OCA), bleeding tendency, and progressive pulmonary fibrosis, ultimately diagnosed with HPS through platelet transmission electron microscopy. The patient received nintedanib, an antifibrotic agent, which appeared to stabilize pulmonary function for approximately 18 months. Genetic testing revealed a novel homozygous splice site variant in HPS4 (NM_022081.6 c.1713+1delG), predicted to result in splice disruption and nonsense-mediated mRNA decay. Based on in silico analysis, the variant was considered pathogenic. To contextualize this case, we reviewed all published HPS4-related cases and identified 51 reported patients carrying 37 unique mutations, including 16 nonsense, 8 frameshift, 7 splice-site, 5 missense, and 1 gross insertion variant. Our findings broaden the mutational spectrum of HPS4 and support the utility of nintedanib in managing HPS-associated interstitial lung disease. It also underscores the potential for pharmacologic intervention to alter the disease trajectory in HPS, particularly in resource-limited settings where lung transplantation is not widely accessible.

15 November 2022 in Blood
Verified
Journal Article
Open access
APAbhishek Pandya
Abhishek Pandya
SKSupreet Kaur
Supreet Kaur
QLQianqian Liu
Qianqian Liu
JMJoel Edmund Michalek
Joel Edmund Michalek
ADAdolfo Enrique Diaz Duque
Adolfo Enrique Diaz Duque

20 May 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JGJuan Francisco Molina-de la Garza
Juan Francisco Molina-de la Garza
ADAdolfo Enrique Diaz Duque
Adolfo Enrique Diaz Duque
MMMichelle Janania Martinez
Michelle Janania Martinez
PSPrathibha Surapaneni
Prathibha Surapaneni
TSTyler William Snedden
Tyler William Snedden
QLQianqian Liu
Qianqian Liu
E20083 Background: Non-Hodgkin Lymphoma (NHL) continues to be in the top 10 of all cancer related deaths. Discrepancies exist among world regions in lymphoma subtype incidence, with a percentage of DLBCL being higher in Latin America versus Nordic countries. T cell lymphomas (TCL) are reported to be more common in east Asia than in the Western hemisphere.The geographic differences in distribution along with under representation of ethnic minorities across all lymphoma subtypes, establish the basis of our analysis at the only NCI-designated cancer center within a Hispanic (H) predominant patient population. We aim to describe our population diagnosed with Hodgkin Lymphoma (HL) and NHL and compare to known overall global and USA statistics. Methods: Observational study, retrospectively analyzed patients with diagnosis of Lymphoma (HL and NHL). The patients received care at UT Health San Antonio, the biggest Hispanic serving Academic Institution in South Texas, between 2008-2018. Key variables included age, gender, race/ethnicity, stage, treatment received, vitality at 3 and 5 years. Continuously distributed outcomes were summarized with the mean and standard deviation and categorical outcomes were summarized with frequencies and percentages. Primary end point was to characterize distribution of HL and NHL by subtypes in our Cancer Center and compare to North American and overall global distribution. Results: A total of 685 patients with lymphoma were identified. Of the NHL subtypes; DLBCL was the most common identified (209, 31%), (FL) was the most common indolent lymphoma (IL) among all demographic groups (123, 26%), followed by HL (116, 17%) which was more common among non-Hispanic (NH) subgroup (73, 63% vs 42, 36%). Among the TCL, CTCL – Mycosis fungoides was the most common subtype (18, 35%) followed by ALK negative ALCL (12, 24%). Incidence by Gender: The percentage of males (M) was slightly higher vs. females (F) in all subtype lymphoma diagnoses, M (352, 51%), F (333, 49%). M had a higher incidence in DLBCL (108, 52% vs 101, 48%), BL (9, 69% vs 4, 31%), and HL (67, 58% vs 49, 44%). Incidence by Race: Total lymphoid neoplasm rates were higher for H (383, 57%) than NH (293, 43%), other (1, 0.2%), not specified (5, 1%). H had a higher incidence in all subtype lymphomas except for Nodular lymphocyte predominant HL (5, 63% vs 3, 37%). Conclusions: Our Hispanic Hispanic Serving Academic Institution, the distribution of lymphomas doesn’t change when compared with previous reported data. Our population and distribution of lymphoma subtypes are similar to global and USA data.